Century Therapeutics, Inc.
IPSC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850119
In the last 90 days, Century Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 100 institutions reported holding it in 13F filings for Q2 2026, worth $387.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Century Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 2 insiders, $10.4K in total
- Insiders trading
- 2
- Net value
- −$10.4K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Century Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Russotti Gregory | See Remarks | 509,198 | Sep 15, 2026 | 8 |
| Carr Douglas | SVP Finance & Operations | 502,907 | Sep 15, 2026 | 12 |
| Pfeiffenberger Brent | President and CEO | 3,633,839 | Sep 15, 2026 | 14 |
| Truitt Joseph | Director | – | Sep 10, 2026 | 1 |
| Cowan Chad | Chief Scientific Officer | 1,175,322 | Jun 15, 2026 | 7 |
| Quimi Daphne | Director | 5,000 | Jun 12, 2026 | 1 |
| Blackwell Kimberly | Director | – | Jun 12, 2026 | 1 |
| Riva Alessandro | Director | – | Jun 12, 2026 | 1 |
| Lee Han Myung | Director | – | Jun 12, 2026 | 2 |
| Murphy Martin Patrick | Director | – | Jun 12, 2026 | 2 |
| Jimenez Joseph | Director | – | Jun 16, 2025 | 0 |
| Butitta Cynthia M | Director | – | Jun 16, 2025 | 0 |
| Walbert Timothy P | Director | – | Jun 16, 2025 | 0 |
| Carlo Rizzuto | Director | – | Jun 16, 2025 | 0 |
| Farid Adrienne | Chief Operations Officer | 250,141 | Jun 11, 2025 | 0 |
| Conn Morgan | Chief Finanical Officer | 79,648 | Mar 12, 2025 | 0 |
| Levitsky Hyam | President of R&D | 24,000 | Mar 11, 2024 | 0 |
| Diem Michael Craig | Chief Financial Officer | 253,533 | Nov 3, 2023 | 0 |
| Borges Luis | Chief Scientific Officer | 256,535 | Apr 5, 2023 | 0 |
| Flores Osvaldo | Chief Executive Officer | – | Feb 6, 2023 | 0 |
| Versant Venture Capital VI, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Ventures VI GP-GP, LLC | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Ventures VI GP, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Vantage II, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Vantage II GP-GP, LLC | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Vantage II GP, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Casdin Eli | Director | – | Jun 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2024 (view filing) | May 20 | 1 day | Russotti GregorySee Remarks | SSale | −5.00K | $3.00 | −$15.0K | −1.7%287.3K after | 10b5-1 |
| May 7, 2024 (view filing) | May 6 | 1 day | Russotti GregorySee Remarks | SSale | −5.00K | $3.12 | −$15.6K | −1.7%292.3K after | 10b5-1 |
| May 7, 2024 (view filing) | May 3 | 4 days | Carr DouglasSVP Finance & Operations | SSale | −257 | $3.11 | −$799.27 | −0.1%317.3K after | |
| May 7, 2024 (view filing) | May 3 | 4 days | Farid AdrienneChief Operations Officer | SSale | −913 | $3.11 | −$2.84K | −0.7%137.2K after | |
| Apr 24, 2024 (view filing) | Apr 22 | 2 days | Russotti GregorySee Remarks | SSale | −5.00K | $3.10 | −$15.5K | −1.7%297.3K after | 10b5-1 |
| Mar 8, 2024 (view filing) | Mar 6-7 | 2 days | Farid AdrienneChief Operations Officer | SSale | −53.5K | $5.04 | −$269.5K | −31.9%114.1K after | 2 lots |
| Feb 21, 2024 (view filing) | Feb 16 | 5 days | Farid AdrienneChief Operations Officer | SSale | −485 | $4.86 | −$2.36K | −0.4%114.1K after | |
| Feb 7, 2024 (view filing) | Feb 5-6 | 2 days | Carr DouglasSVP Finance & Operations | SSale | −1.20K | $4.14 | −$4.97K | −0.4%303.6K after | 2 lots |
| Feb 7, 2024 (view filing) | Feb 5-6 | 2 days | Farid AdrienneChief Operations Officer | SSale | −3.82K | $4.14 | −$15.8K | −3.2%114.1K after | 2 lots |
| Mar 23, 2023 (view filing) | Mar 21-23 | 2 days | Borges LuisChief Scientific Officer | SSale | −144.9K | $3.72 | −$539.6K | −36.8%249.1K after | 3 lots |
| Aug 11, 2022 (view filing)4:55 PM ET | Aug 9 | 2 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −550.0K | $13.03 | −$7.17M | −4.4%11.8M after |